Mar 01, 2024 / 01:00PM GMT
Operator
Good morning and welcome to the Y-mAbs Therapeutics earnings conference call for the fourth quarter and full year of 2023. (Operator Instructions) As a reminder, today's conference will be recorded.
And I'll now turn the call over to Y-mAbs Head of Investor Relations, Courtney Dugan.
Courtney Dugan - Y-mAbs Therapeutics Inc - VP, Head of IR
Thank you, operator, and good morning, everyone. And welcome to the Y-mAbs Fourth Quarter and Full Year 2023 financial results conference call. We issued a press release with our results yesterday after market close and the press release and accompanying slides are available on the IR section of our website.
Let me quickly remind you that the following discussion contains certain statements that are considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995.
Such statements include, but are not limited to, statements about our business model and development, commercialization and product distribution plans and expectations with respect to early trial
Q4 2023 Y-mAbs Therapeutics Inc Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot